OPTHEA LTD
Research OPTHEA LTD (UKJ) on Bullrun: market cap EUR 8.89M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerUKJ
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 8.89M
- Financial periodFY2025
- RevenueAUD 25.00K
- Revenue growth-80.0%
- Net income-AUD 162.79M
- Free cash flow-AUD 158.66M
Valuation Snapshot
latest market cap is EUR 8.89M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 25.00K | -AUD 162.79M | -AUD 158.66M | n/a | -0.13 | AUD 48.44M | AUD 0 | -AUD 201.07M |
| FY2024 | AUD 125.00K | -AUD 220.24M | -AUD 161.05M | n/a | -0.35 | AUD 172.47M | AUD 141.65M | -AUD 75.81M |
| FY2023 | AUD 108.00K | -AUD 142.52M | -AUD 120.63M | -54.1% | -0.28 | AUD 89.19M | AUD 85.84M | -AUD 5.85M |
| FY2022 | AUD 90.68K | -AUD 92.82M | -AUD 71.35M | -45.3% | -0.23 | AUD 44.63M | AUD 0 | AUD 47.98M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-29 | EUR 8.89M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About OPTHEA LTD
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OPTHEA LTD's market cap?
OPTHEA LTD's market capitalization is EUR 8.89M.
What does OPTHEA LTD do?
Ceryvyn Therapeutics Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026.